Chengde

This research aims to understand how well participants with obesity tolerate the drug RAY1225, while also exploring its effectiveness. The study focuses on adults with obesity, including those with certain related health conditions like hypertension or fatty liver disease. It is a Phase 2 clinical trial lasting about six months for each participant. Participants will receive either RAY1225 or a placebo through subcutaneous (under the skin) injection. The study is designed to compare these two groups to assess safety, tolerability, and changes in body weight. Reliable contraception is required during the study and for six months after the last dose to ensure safety. Throughout the study, participants will be monitored for changes in body weight from the start to week 26. Safety and tolerability assessments will also be conducted to track any side effects or issues. The total duration of participation for each individual is approximately six months, with regular check-ins to evaluate progress and well-being.

Researchers are evaluating the safety and effectiveness of Senl-T7 CAR T cells in patients with relapsed or refractory CD7-positive acute T lymphoblastic leukemia or T lymphoblastic lymphoma. This open, prospective, dose-escalation clinical trial also collects pharmacokinetic and pharmacodynamic data of Senl-T7 to better understand its behavior in the body. The study focuses on patients who have not responded to prior treatments or have experienced recurrence of their disease. Patients in this study will receive treatment with Senl-T7, a type of CAR T cell therapy that targets CD7 on tumor cells. Before receiving the CAR T cells, patients will undergo a preconditioning treatment to prepare their body. After infusion, patients will be closely monitored for side effects and treatment response. The trial uses an anti-CD7 single-chain variable fragment combined with human 4-1BB and CD3ζ components in the CAR design to direct the therapy against cancer cells. During the study, participants will be evaluated for adverse events within the first month after infusion and remission status at three months. Researchers will perform various assessments including laboratory tests, physical exams, and monitoring of blood oxygen levels. Safety and disease response will be carefully tracked throughout participation, which includes ongoing follow-up to ensure participant well-being and gather comprehensive data on the therapy's effects.